Clinical Trial Update: Prolonged Enoxaparin in Primary Percutaneous Coronary Intervention [Phase 4]

View source ↗

Summary

Phase 4 trial update on prolonged enoxaparin in primary percutaneous coronary intervention for myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust | Conditions: Myocardial Infarction | Phase 4 | Status: COMPLETED